Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
Human papillomavirus (HPV) is predominantly associated with HPV-related cancers, however, the precise mechanisms underlying the HPV-host epigenetic architectures in HPV carcinogenesis remain elusive. Here, we employed high-throughput chromosome conformation capture (Hi-C) to comprehensively map HPV16/18-host chromatin interactions. Our study identified the transcription factor Sp1 as a pivotal mediator in programming HPV-host interactions. By targeting Sp1, the active histone modifications (H3K27ac, H3K4me1, and H3K4me3) and the HPV-host chromatin interactions are reprogrammed, which leads to the downregulation of oncogenes located near the integration sites in both HPV (E6/E7) and the host genome (KLF5/MYC). Additionally, Sp1 inhibition led to the upregulation of immune checkpoint genes by reprogramming histone modifications in host cells. Notably, humanized patient-derived xenograft (PDX-HuHSC-NSG) models demonstrated that Sp1 inhibition promoted anti-PD-1 immunotherapy via remodeling the tumor immune microenvironment in cervical cancer. Moreover, single-cell transcriptomic analysis validated the enrichment of transcription factor Sp1 in epithelial cells of cervical cancer. In summary, our findings elucidate Sp1 as a key mediator involved in the programming and reprogramming of HPV-host epigenetic architecture. Inhibiting Sp1 with plicamycin may represent a promising therapeutic option for HPV-related carcinoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:588 |
|---|---|
| Enthalten in: |
Cancer letters - 588(2024) vom: 28. Apr., Seite 216809 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cao, Canhui [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 12.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2024.216809 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369613686 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369613686 | ||
| 003 | DE-627 | ||
| 005 | 20240412232957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2024.216809 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM369613686 | ||
| 035 | |a (NLM)38471646 | ||
| 035 | |a (PII)S0304-3835(24)00202-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cao, Canhui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Three-dimensional chromatin analysis reveals Sp1 as a mediator to program and reprogram HPV-host epigenetic architecture in cervical cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Human papillomavirus (HPV) is predominantly associated with HPV-related cancers, however, the precise mechanisms underlying the HPV-host epigenetic architectures in HPV carcinogenesis remain elusive. Here, we employed high-throughput chromosome conformation capture (Hi-C) to comprehensively map HPV16/18-host chromatin interactions. Our study identified the transcription factor Sp1 as a pivotal mediator in programming HPV-host interactions. By targeting Sp1, the active histone modifications (H3K27ac, H3K4me1, and H3K4me3) and the HPV-host chromatin interactions are reprogrammed, which leads to the downregulation of oncogenes located near the integration sites in both HPV (E6/E7) and the host genome (KLF5/MYC). Additionally, Sp1 inhibition led to the upregulation of immune checkpoint genes by reprogramming histone modifications in host cells. Notably, humanized patient-derived xenograft (PDX-HuHSC-NSG) models demonstrated that Sp1 inhibition promoted anti-PD-1 immunotherapy via remodeling the tumor immune microenvironment in cervical cancer. Moreover, single-cell transcriptomic analysis validated the enrichment of transcription factor Sp1 in epithelial cells of cervical cancer. In summary, our findings elucidate Sp1 as a key mediator involved in the programming and reprogramming of HPV-host epigenetic architecture. Inhibiting Sp1 with plicamycin may represent a promising therapeutic option for HPV-related carcinoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cervical cancer | |
| 650 | 4 | |a Hi-C | |
| 650 | 4 | |a Human papillomavirus | |
| 650 | 4 | |a Immune checkpoint genes | |
| 650 | 4 | |a PD-1 immunotherapy | |
| 650 | 7 | |a Chromatin |2 NLM | |
| 650 | 7 | |a Oncogene Proteins, Viral |2 NLM | |
| 650 | 7 | |a Papillomavirus E7 Proteins |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a SP1 protein, human |2 NLM | |
| 700 | 1 | |a Xu, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Zhixian |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Miaochun |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Shitong |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhi, Wenhua |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Da |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Yifan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Juncheng |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Wencheng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xiaoyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Sung, WingKin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Gang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Ding |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guoliang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 588(2024) vom: 28. Apr., Seite 216809 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:588 |g year:2024 |g day:28 |g month:04 |g pages:216809 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2024.216809 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 588 |j 2024 |b 28 |c 04 |h 216809 | ||